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Abstract
Background: Conflict of interest (COI) of clinical practice guideline (CPG) sponsors and authors is an important potential
source of bias in CPG development. The objectives of this study were to describe the COI policies for organizations currently
producing a significant number of CPGs, and to determine if these policies meet 2011 Institute of Medicine (IOM) standards.
Methodology/Principal Findings: We identified organizations with five or more guidelines listed in the National Guideline
Clearinghouse between January 1, 2009 and November 5, 2010. We obtained the COI policy for each organization from
publicly accessible sources, most often the organization’s website, and compared those polices to IOM standards related to
COI. 37 organizations fulfilled our inclusion criteria, of which 17 (46%) had a COI policy directly related to CPGs. These COI
policies varied widely with respect to types of COI addressed, from whom disclosures were collected, monetary thresholds
for disclosure, approaches to management, and updating requirements. Not one organization’s policy adhered to all seven
of the IOM standards that were examined, and nine organizations did not meet a single one of the standards.
Conclusions/Significance: COI policies among organizations producing a large number of CPGs currently do not measure
up to IOM standards related to COI disclosure and management. CPG developers need to make significant improvements in
these policies and their implementation in order to optimize the quality and credibility of their guidelines.
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Introduction
Clinical practice guidelines (CPGs) are ‘‘statements that include
recommendations intended to optimize patient care that are
informed by a systematic review of evidence and an assessment of
the benefits and harms of alternative care options,’’ according to
the Institute of Medicine (IOM) [1]. CPGs can influence the care
delivered by a large number of healthcare providers and thus the
outcomes of patients [2], so their quality is critically important.
High-quality guidelines have the potential to promote the use of
effective clinical services, decrease undesirable practice variation,
reduce the use of services that are of minimal or questionable
value, increase the use of effective but underused services, and
target services to populations most likely to benefit [3]. High-
quality guidelines are valid (unbiased), reproducible, clinically
applicable to the populations of interest, flexible, clearly presented,
developed through a multidisciplinary process, reviewed on a
regular schedule, and well-documented [3]. CPGs may improve
processes of care [2,4,5], however data on the effectiveness of
CPGs on health outcomes are sparse and conflicting [1,2,4–6].
Conflict of interest (COI) is an important potential source of
bias in the development of CPGs. A COI is a set of conditions in
which professional judgment concerning a primary interest (such
as the health and well being of a patient or the validity of research),
is unduly influenced by a secondary interest [7]. There are data
that suggest an association between author or funder COI and
study outcomes [8–11] and between COI and systematic review
conclusions [12]. Data on the prevalence of industry relationships
of guideline sponsors and authors are limited and dated, however
[13–16], and evidence of the effect of these relationships on
guideline recommendations is confined to case studies [17].
Nonfinancial interests may also be powerful motivators for
guideline authors [18], including the advancement of medical
science, career advancement, fulfillment of a desire to do good,
opportunity to publish, notoriety, future success in obtaining
funding for research, and increased sense of self worth [19].
Recent IOM reports highlight the importance of COI in
healthcare [20], systematic reviews [21], and CPGs [1], and
provide standards for disclosure and management of COI. The
extent to which current CPG organizational policies align with
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study was to describe the COI policies of organizations currently
producing a large number of CPGs, to compare these policies to
the recent IOM standards related to COI in CPG development
[1], and to identify characteristics of organizations that correlate
with policies that meet these standards.
Methods
We identified organizations that had five or more guidelines
listed in the National Guideline Clearinghouse (NGC) (http://
www.guideline.gov) that were published between January 1, 2009
and the date of our search (November 5, 2010). We selected this
cohort in order to examine the policies of organizations that have
the potential for a major effect on physician behavior and patient
outcomes. The NGC, funded by the Agency for Healthcare
Research and Quality (AHRQ), was established in January of
1999, ‘‘to provide physicians and other health professionals, health
care providers, health plans, integrated delivery systems, purchas-
ers, and others an accessible mechanism for obtaining objective,
detailed information on clinical practice guidelines and to further
their dissemination, implementation, and use’’ [22]. The inclusion
criteria for guidelines within the NGC are:
1) The CPG contains systematically developed statements that
include recommendations, strategies, or information that
assists physicians and/or other health care practitioners and
patients to make decisions about appropriate health care.
2) The CPG was produced under the auspices of medical
specialty associations; relevant professional societies, public
or private organizations, government agencies at the
Federal, State, or local level; or health care organizations
or plans.
3) Corroborating documentation can be produced and verified
that a systematic search and review of existing scientific
evidence was performed during the guideline development.
4) The full text guideline is available upon request in the
English language.
5) The guideline is current, in that it was developed, reviewed,
or revised within the last 5 years.
Two authors (HKH, BUB) independently searched for each
organization’s COI policy on the organization’s website and
through a general internet search. Only policies that were specific
to CPG development were examined further: the policy was
required to either include a statement specifically regarding CPGs
or be included in a CPG development handbook, and at a
minimum address COI for CPG panel members. Policies that
covered a variety of organizational activities were not examined
further because such general policies did not address adequately
address the issues of COI relevant to CPG development. If the
guideline developer was US-based, the authors also determined if
the CPG organization was signed onto the Council of Medical
Specialty Societies’ (CMSS) Code for Interactions with Compa-
nies, by examining the CMSS website [23]. CMSS, a collabora-
tion of almost 40 US-based medical specialty organizations, issued
a revised code in March, 2011 to provide guidance for members
on how to minimize and manage conflicts of industry that arise
from their relationships with companies that produce drugs,
devices, and other healthcare interventions. Underpinned by the
principles of independence and transparency, the CMSS code
provides specific guidance for the conduct of educational
programs, business interactions, receipt of funding support,
sponsorship, and advocacy, among others.
We did not include information contained within the CPG or in
the summary provided by the NGC as the former was invariably
insufficient to assess the organization’s policy and the latter was
information provided by the organization to the NGC after the
guideline was completed. We did not contact organizations for
additional information, nor did we try to obtain information from
organizations with protected websites for members only, because
we wanted to include only information that was publicly available
to users of CPGs, and our past experiences trying to obtain
unpublished COI policies suggested that such an approach was
not likely to be productive.
One author abstracted information on each organization’s COI
policy into a pre-specified template in ExcelH, and those data were
checked by a second author. The data abstracted from each policy
included when disclosures were obtained, from whom, over what
time period, the types of COI (financial or intellectual), and how
disclosures were managed. Data were synthesized across guidelines
using descriptive statistics and a qualitative synthesis. We used a
logistic regression model to explore the association between
whether an organization had a CPG-specific COI policy and
pre-specified predictors included type of organization, the number
of CPGs produced between 2009 and our search date, and
whether or not the organization was based in the US.
We compared the COI policy of each guideline organization to
the COI-related standards in the 2011 IOM report (Table 1) [1]
for the purpose of describing the degree to which organizations are
already meeting these standards and the gaps that need to be
addressed. We selected the IOM standards as a comparator for
our cohort of guidelines because this report is the most recent,
large-scale compendium of evidence and recommendations for
guideline development in healthcare that we are aware of. We are
aware of extensive efforts across North American guideline groups
to implement these standards. We assessed the seven IOM
standards that were deemed evaluable at the level of the
organizational policy (standards 2.1, 2.2a, 2.2b, 2.3, 2.4a, 2.4c,
2.4d). We did not assess standards that were best assessed at the
level of the CPG (standard 1.1) or standards that were unlikely to
be included in an organization’s COI policy (standard 2.4b, 2.4e).
Three authors (SLN, HKH, BUB) independently made a
determination as to whether each organization’s policy met each
IOM standard and then consensus was achieved through
discussion. Inter-rater reliability was assessed by using Kappa
statistics for each standard and overall for the seven standards
combined.
We then explored pre-specified predictors for organizations
fulfilling these IOM standards, using the same variables that we
used in our examination of whether each organization had a COI
policy or not. The association between meeting each standard or
at least one standard and the predictors was assessed using a
logistic regression model. The association between meeting any
IOM standard and the predictors was assessed using a logistic
generalized estimating equation (GEE) model, accounting for
correlation among multiple standards within each organization.
The association between the proportion of standards met in each
organization and the predictors was explored using a linear
regression model.
Results
Characteristics of Organizations Producing CPGs
596 CPGs were published in NGC between 2009 and the date
of our search in 2010, by 118 organizations listing at least one
guideline. Of these organizations, 37 fulfilled our inclusion criteria,
publishing 392 guidelines (66% of the total of 596 CPGs) (Table 2).
Conflict of Interest and Clinical Guidelines
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20 guidelines, while one organization published more than 40
[24]. Professional (56.7%) and government (29.7%) organizations
made up the majority of the 37 organizations.
Conflict of Interest Policies
Seventeen of the 37 organizations (45.9%) had a COI policy
that was publicly accessible and applicable to the development of
CPGs (Table 3). The remaining organizations either did not have
a policy or it was not publicly available (43.2%), or the only
identified policy was not explicitly related to CPG development
(10.8%). Organizational characteristics were not significantly
associated with the presence of a COI policy, including the
production of fewer CPGs (p=0.24), governmental compared to a
professional organization (p=0.65), and based in the US
compared to other countries (p=0.17).
Twelve [25–36] of the 17 organizations (71%) with a COI
policy implemented their policy within the last 5 years; one
organization [37] had a policy dating back to 2003. Four
organizations [25,27–29] signed onto the CMSS Code of
Interactions with Companies [23], however, only one organization
[25] acknowledged their CMSS affiliation website and within their
COI policy.
COI was variably defined across the 17 policies (Table 3), of
which 15 included the terms ‘‘financial’’ or ‘‘commercial’’ [24–
38]. Disclosure of specific financial relationships varied among
organizations: the most common types were paid consultancies,
research or salary support, patents or royalties, equity or stock, and
gifts. Only three organizations [26,27,36] specified a dollar-value
threshold for required reporting of a financial interest.
The types of non-financial COI described in the policies also
varied (Table 3). Eleven organizations (65% of 17) specifically
required that intellectual or other non-financial COI be disclosed
[25,26,28,29,32–38]. Four of these organizations did not provide a
definition for non-financial COI, but rather used terms such as
‘‘intellectual’’ or ‘‘other related’’ conflicts [25,29,35,38]. The
remaining seven organizations provided more detailed, and very
heterogeneous, descriptions [26,28,32–34,36,37]. One organiza-
tion required the disclosure of competing beliefs, academic
institutions, societies and publications [28], while another organi-
zation required the reporting of substantial career efforts (effort
devoted to procedures currently performed in clinical practice)
[29]. One organization [26] used the definition of intellectual COI
as proposed by Guyatt and colleagues [18] where an attachment
to a specific viewpoint as developed through academic and other
activities could unduly affect an individual’s judgment about a
specific guideline recommendation.
Disclosures
All organizations required disclosure from all guideline devel-
opment group members (Table 4). The editorial board (5.8%),
systematic review authors (5.8%), expert reviewers (17.6%), and
other guideline contributors (5.8%) such as expert advisors and
staff were also specifically required to disclose in some policies.
Seven organizations (23.5%) required that the disclosure policy
extend to relatives or dependents of guideline development group
members [26,28–30,35,36,38].
Disclosures are collected at various time points across the
organizations, (Table 4) most commonly at the time of appoint-
ment to a guideline panel or prior to beginning deliberations. Two
organizations addressed updating of COI, either throughout the
CPG process [25] or just prior to CPG publication [29]. The
reporting period for COI ranged between the prior 12 to 60
months (median 12 months).
Seven organizations (41.2%) limited the disclosure to only those
that were relevant to the content of the CPG (Table 2)
[25,28,29,32–34,36]. In most organizations relevance was not
defined, however, although three organizations that shared a
common COI policy require disclosure for personal payments,
‘‘which may either relate to the manufacturer or owner of a
product or service being evaluated, in which case it is regarded as
‘specific’ or to the industry or sector from which the product or
service comes, in which case it is regarded as ‘non-specific’ ’’ [32–
34].
Table 1. Institute of Medicine standards for developing trustworthy clinical practice guidelines (2011)[1].
IOM Standard
1.1: * The process by which a CPG is developed and funded should be detailed explicitly and be publicly accessible.
2.1:{ Prior to selection of the CPG group, individuals being considered for membership should declare all interests and activities potentially resulting in COI with
development group activity, by written disclosure to those convening the guideline development group. Disclosure should reflect all current and planned commercial,
noncommercial, intellectual, institutional, and patient/public activities pertinent to the potential scope of the CPG.
2.2a: All COI of each GDG member should be reported and discussed by the prospective development group prior to the onset of his or her work.
2.2b: Each panel member should explain how his or her COI could influence the CPG development process or specific recommendations.
2.3: ¥ Members of the GDG should divest themselves of financial investments they or their family members have in, and not participate in marketing activities or
advisory boards of, entities whose interests could be affected by CPG recommendations.
2.4a: Whenever possible, GDG members should not have COI.
2.4b:* In some circumstance, a GDG may not be able to perform its work without members who have COI, such as relevant clinical specialists who receive a substantial
portion of their income from services pertinent to the CPG.
2.4c: Members with COI should represent not more than a minority of the guideline development group.
2.4d: The chair or co-chairs should not be a person(s) with COI.
2.4e:* Funders should have no role in CPG development.
Abbreviations: COI, conflict of interest; CPG: clinical practice guideline; GDG, guideline development group.
(*)We did not assess this standard as it would not be included in a COI policy.
{An organizations’ COI policy must include all listed criteria in order to meet this standard in Table 5.
¥Not applicable to COI policies that exclude any COI among guideline panel members.
doi:10.1371/journal.pone.0037413.t001
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Eleven organizations (64.7% of 17) delineated strategies to
manage COI after disclosure, with considerable variation in these
approaches (Table 4). Advisory panels (5.8%), the CPG committee
(23.5%), committee chairs (5.8%), or another party (e.g., funder of
the CPG) (17.6%) assessed the disclosures. In some cases the same
body of individuals assessed and managed the disclosures (17.6%).
More commonly, however, a party separate from those involved in
the assessment of disclosures devised a management plan: advisory
panel (17.6%), the CPG chair (5.8%), or an ethics committee
(11.8%). For 47% of organizations, a significant conflict resulted in
recusal from the CPG development group or abstention from the
final recommendation process. One policy detailed penalties for
non-compliance with the organization’s policy [28], while two
other organizations stated that non-compliance would lead to
disciplinary action [27,29].
IOM Standards for Reporting Conflicts of Interest in
Clinical Practice Guidelines
None of the 17 organizations with a CPG-specific COI policy
met all seven IOM standards specific to COI (Table 5). The
policies of eight organizations [25,26,28,29,32–34,36,38], howev-
er, met at least one of the seven standards, with five organizations
meeting at least four [25,29,32–34]. The standard most frequently
met was 2.1 (n=7) and 2.2a (n=8). None of the organization
characteristics was statistically significantly associated with meeting
any standard, including number of CPGs listed in NGC by that
organization in our 2009 to 2010 cohort (p=0.21); professional
organization compared to government sponsor (p=0.81); and US-
based organization versus other countries (p=0.85). Regression
models examining these same predictors for meeting each
individual standard, at least one standard, as well as the proportion
of standards met for each organization were also not significant
(p,0.05).
The agreement among the three assessors for all seven IOM
standards across all 17 policies was 94.1% (95% CI, 88.3% to
97.6%). Agreement for specific standards ranged from 76.5%
(standard 4a) to 100.0% (standards 2b, 3, 4d). The overall Kappa
statistic for inter-rater reliability among the three reviewers was
0.88.
Discussion
Fewer than half of organizations that have recently listed a large
number of guidelines in the NGC have a COI policy directly
related to CPGs. Of organizations with such policies, these vary
widely with respect to types of COI addressed, from whom
disclosures are collected, monetary thresholds for disclosure,
approaches to management, and updating requirements. Not
one organization’s policy adhered to all seven of the IOM 2011
standards applicable to COI policies for CPGs, and approximately
half of these organizations do not adhere to a single one of these
standards.
There is a need for extensive improvements in COI policies for
organizations producing CPGs. Every developer must have a COI
policy specific to CPGs: a general COI policy for the organization
or a policy that relates to research subjects, for example, is not
adequate to address the issues of secondary interests relevant to
guideline development. Guidelines involve multiple groups of
individuals and processes, and the COI of all of these must be
disclosed: authors of the systematic review, the guideline panel
members, and other individuals involved in the formulation and
approval processes. COI policies for CPGs must also address
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37413Table 3. Organizational policies on financial and non-financial conflict of interest (n=17).
Organization Policy definition of COI
Types of
financial COI
Financial
threshold
Non-financial
COI
addressed
Types of
non-financial
COI
Precludes
industry
funding
Relevance
mentioned
ABM [25] All financial and uncompensated
relationships with companies
S NR Yes I Yes Yes
AAN [29] A financial stake in the success or failure
of the products appraised in the CPG
C, S, P, E, O NR* Yes I Yes Yes
AASLD [26] If a person or their immediate family
might gain financially or non-financially
from the actions of the person while acting
on behalf of AASLD. If a person who serves
AASLD also serves another organization,
whose mission overlaps that of AASLD, in
a capacity that can potentially put that
organization in direct competition with
AASLD thereby impeding the ability of
AASLD to fulfill its mission. Conflicts of
interest are further defined as any
circumstances that create a risk that
professional judgment or actions regarding
a primary interest will be unduly influenced
by a secondary interest. Primary interests are
those associated with the stated mission of
the AASLD. Secondary interests may be
financial or non-financial in nature
C, S, P, E, G, O $5,000 Yes V Yes No
ACOG [27] Not defined C, S, P, E, G, O $25–$5,000{ No NA No No
ADA [38] Duality of interest: individuals have
material interests outside the ADA that
could influence them or could be
perceived as influencing them to act
contrary to the interests of the ADA
and for their own personal benefit or
that of a family member or a business
associate
C, S, E NR Yes I No No
AUA [28] Relationships or associations with
organizations, persons, corporations or
enterprises that may affect or be
perceived to affect one’s judgment
or decision-making
C, S, P, E, O NR Yes V Yes No
EAU [24] Situations involving a duality of interest
which might be interpreted as COI
NA (financial
COI not
addressed
specifically)
NA No NA No No
ICSI [30] Any potential conflict and competing
interests with any organization with
commercial, proprietary, or political
interests relevant to the topics covered
by ICSI
ON R N o N A N o N o
MQIC [31] Relationships with pharmaceutical
companies, biomedical device
manufacturers, or other corporations
whose products or services are related
to the guideline subject matter
C, S, E, G, O NR No NA No No
NCC-MH [32]
NCC-WCH [33]
NICE [34]
A personal pecuniary interest involves
a current personal payment, which may
either relate to the manufacturer or owner
of a product or service being evaluated, in
which case it is regarded as ‘specific’ or to
the industry or sector from which the
product or service comes, in which case
it is regarded as ‘non-specific’
C, S, P, E NR Yes V, I No Yes
PEC [43] Not defined O NR No NA No No
RNAO [44] Not defined1 NA NA No NA No No
Conflict of Interest and Clinical Guidelines
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37413management of the disclosures, starting with the requirement that
the guideline panel chair and co-chair have no relevant COI.
There are important implications of our findings for users of
CPGs. Given the evidence that financial relationships of
researchers are associated with study findings [8–11,39] and that
guideline panel composition correlates with panel recommenda-
tions [40], the reader needs to have ready access to accurate and
up-to-date disclosures, and be assured that secondary interests
have been appropriately managed.
Nonfinancial COI may be an important source of bias, and two-
thirds of organizations make some mention of this type of COI in
their policies. Definitions are variable, however, and often vague
and difficult to interpret, potentially leading to inconsistent and
incomplete reporting. The current knowledge base on the impact
of nonfinancial COI on decision making is sparse, so that the
development of evidence-based guidance on the disclosure and
management of nonfinancial COI is difficult at the present time.
The IOM standards related to COI do not address all of the
important issues for CPG developers and users. In particular, these
standards do not address accessibility of COI policies, the
relevance of secondary interests to the primary interest, and the
optimal presentation of disclosures. We often encountered a great
deal of difficulty locating COI policies: these policies should be
readily accessible from the guideline organization’s website.
Policies on disclosures should address both relevance and an
appropriate level of detail. Inadequate guidance within COI
policies on these issues may reflect lack of evidence on both the
relationship between specific types of conflicts and risk of bias, and
what constitutes optimal disclosures for the reader. IOM standards
also do not address accountability for accurate disclosures and
adherence to the policy within the organization. In other words,
adherence to these seven IOM standards does not ensure an
optimal COI policy.
There are limitations to our approach. Most importantly, we
did not assess if and how these policies were applied during CPG
development and publication. Nor did we examine the impact of
each organization’s policy on their processes, disclosures, recom-
mendations, and the use and interpretation of the guidelines by
healthcare providers. Our descriptive work provides the basis for
these important next steps in evaluating the nature and effect of
COI policies in CPG development.
It is possible that our summary of these organizations’ policies is
not up to date. Given the current attention to COI policies by
biomedical journals [41,42] and organizations producing CPGs
[1,23], the COI policies for the organizations that we examined
may have changed between development of the CPGs listed on the
NGC website, our examination of the policy, and the present. Our
information on specific policies may be incomplete in spite of
having two independent persons identifying COI policies due to
difficulty locating policies in various locations in linked websites.
We did not contact organizations for additional, unpublished
information, nor did we try to obtain information from
organizations with protected websites. We felt that if the guideline
was in the public domain the COI policy should be there also,
Table 3. Cont.
Organization Policy definition of COI
Types of
financial COI
Financial
threshold
Non-financial
COI
addressed
Types of
non-financial
COI
Precludes
industry
funding
Relevance
mentioned
SIGN [35] Specific interests are those which
relate to a topic or remit of the
particular guideline. Non specific
interests are those which are otherwise
relevant to the work of SIGN. For their
partners or close relatives, interests are
restricted to employment in, or share
holdings in, healthcare organizations
C, S, E, G, O NR Yes NR No No
SOCG [37] Breach of an obligation that has the
effect or intention of advancing one’s
own interest or the interests of others
in a way detrimental to the interests,
or potentially harmful to the public
or the integrity and fundamental
mission of the SOGC
C, G NR Yes V No No
USPSTF [36] Each corporation, company, firm,
research organization, educational
institution, or other organization or
institution (proprietary and not-for-profit,
domestic and foreign) in which you,
your spouse, and dependent children
have significant financial interests that
are related to the subject matter
C, S, P, E $10,000 or
.5%
ownership{
Yes I No Yes
*Financial COI declared in ranges (less than $10,000, $10,000 to $25,000, and greater than $25,000).
{Having a financial interest of greater than $5,000 in an individual pharmaceutical company or an individual manufacturer of medical instruments, devices or
equipment; acceptance of anything with a value greater than $25 for their personal use from an individual pharmaceutical company or an individual manufacturer of
medical instruments, devices or equipment.
{Required to disclosure amounts greater than $10,000 per year or as determined through reference to public prices or other reasonable measure of fair market value, or
represents more than 5% ownership interest in any single entity.
1RNAO requires that all members declare COI in writing during recruitment or selection of guideline panel members, but no other information is provided in their policy.
Key to types of conflict of interest: C: paid consultancy or speaking engagement. S: research or salary support. P: patent or royalties. E: equity or stock. G: gifts. O: other
(e.g., travel grants). I: non-financial or intellectual (not otherwise specified). V: opinion or viewpoint.
Abbreviations: COI, conflict of interest; NA, not applicable; NR, not reported; see Table 1 for abbreviations for the guideline organizations.
doi:10.1371/journal.pone.0037413.t003
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and disclosures. We also encountered challenges in determining if
an organization’s COI policy was specific to CPGs. Two
independent reviewers made this assessment and then came to
consensus, but it is possible that some of the organizations that we
assessed as not having a CPG-specific policy would consider
themselves to have such a policy. We would counter that these
policies need to be more transparent and to address the processes
and individuals involved in CPGs specifically.
The applicability of our findings to other organizations
producing CPGs may be limited. The COI policies of organiza-
tions producing a small number of CPGs (less than 5) may differ
from the policies that we examined. In addition, we focused only
on CPGs published in English and those listed in NGC: the
policies of other organizations may differ from our findings. The
IOM standards were developed by a US-based group of experts,
and thus encompass the American perspective on guideline topics,
methodology, available resources, and the standards target U.S.
patient populations and health care providers. The evidence base
examined in the IOM report encompasses studies from a variety of
international settings, and thus the IOM standards are likely
applicable to guideline development in the Western world.
The IOM standards [1] were released after the publication of
the CPGs examined herein. Thus our goal in comparing the IOM
standards to existing organizational polices was to describe the
current status of these policies and to identify areas where
improvements are needed and not to criticize organizations for not
having met these standards. Our reporting of the gaps in current
approaches may aid organizations in planning updates of their
COI policies and in comparing policies across organizations.
The IOM standards were not intended to be a quality
assessment tool, thus implementing them as such was problematic.
Standard 2.1 addresses both financial and nonfinancial COI, thus
the two types of COI are not distinguished. Many of the standards
are too vague to implement as quality assessment criteria: for
example, standard 2.4a (Table 1).
COI policies among organizations producing a large number of
CPGs currently do not measure up to IOM standards. Policy-
makers, guideline funders, sponsors, and developers, as well as
users need to address and demand improvements. Patients and
populations need trustworthy CPGs, and the accurate disclosure
and subsequent management of COI is essential to achieve that
goal.
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